Masked Chimeric Antigen Receptor for Tumor-Specific Activation

Kershaw, 2013, Gene-engineered T cells for cancer therapy, Nat. Rev. Cancer, 13, 525, 10.1038/nrc3565

Sadelain, 2013, The basic principles of chimeric antigen receptor design, Cancer Discov., 3, 388, 10.1158/2159-8290.CD-12-0548

Davila, 2014, Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci. Transl. Med., 6, 224ra25, 10.1126/scitranslmed.3008226

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134

Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N. Engl. J. Med., 371, 1507, 10.1056/NEJMoa1407222

Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J. Clin. Oncol., 33, 540, 10.1200/JCO.2014.56.2025

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 126, 2123, 10.1172/JCI85309

Jackson, 2016, Driving CAR T-cells forward, Nat. Rev. Clin. Oncol., 13, 370, 10.1038/nrclinonc.2016.36

Gill, 2016, Chimeric antigen receptor T cell therapy: 25years in the making, Blood Rev., 30, 157, 10.1016/j.blre.2015.10.003

Klebanoff, 2016, Prospects for gene-engineered T cell immunotherapy for solid cancers, Nat. Med., 22, 26, 10.1038/nm.4015

Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24

Jensen, 2015, Designing chimeric antigen receptors to effectively and safely target tumors, Curr. Opin. Immunol., 33, 9, 10.1016/j.coi.2015.01.002

Ciardiello, 2002, Anti-epidermal growth factor receptor drugs in cancer therapy, Expert Opin. Investig. Drugs, 11, 755, 10.1517/13543784.11.6.755

Nicholson, 2001, EGFR and cancer prognosis, Eur. J. Cancer, 37, S9, 10.1016/S0959-8049(01)00231-3

Yano, 2003, Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition, Anticancer Res., 23, 3639

Peréz-Soler, 2005, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?, J. Clin. Oncol., 23, 5235, 10.1200/JCO.2005.00.6916

Martinelli, 2009, Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy, Clin. Exp. Immunol., 158, 1, 10.1111/j.1365-2249.2009.03992.x

Galizia, 2007, Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer, Oncogene, 26, 3654, 10.1038/sj.onc.1210381

Desnoyers, 2013, Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index, Sci. Transl. Med., 5, 207ra144, 10.1126/scitranslmed.3006682

Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat. Med., 21, 581, 10.1038/nm.3838

van der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat. Rev. Drug Discov., 14, 499, 10.1038/nrd4597

Rice, 2006, Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands, Protein Sci., 15, 825, 10.1110/ps.051897806

Boulware, 2006, Protease specificity determination by using cellular libraries of peptide substrates (CLiPS), Proc. Natl. Acad. Sci. USA, 103, 7583, 10.1073/pnas.0511108103

Zheng, 2012, Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry, J. Transl. Med., 10, 29, 10.1186/1479-5876-10-29

Fruth, 1988, Human T cell specific proteinase (HuTSP) is encoded by the T cell and natural killer cell specific human Hanukah factor (HuHF) gene, FEBS Lett., 237, 45, 10.1016/0014-5793(88)80168-6

Ulisse, 2009, The urokinase plasminogen activator system: a target for anti-cancer therapy, Curr. Cancer Drug Targets, 9, 32, 10.2174/156800909787314002

Ghosh, 2010, Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array, Biosens. Bioelectron., 26, 424, 10.1016/j.bios.2010.07.106

Antonyak, 2001, Regulation of expression of the components of plasminogen activation system in the leukemic cells, Exp. Oncol., 23, 253

Subik, 2010, The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines, Breast Cancer (Auckl.), 4, 35

Raben, 2005, The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer, Clin. Cancer Res., 11, 795, 10.1158/1078-0432.795.11.2

Xing, 1999, Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation, Int. J. Cancer, 81, 443, 10.1002/(SICI)1097-0215(19990505)81:3<443::AID-IJC19>3.0.CO;2-T

Ma, 2001, Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells, J. Cell Sci., 114, 3387, 10.1242/jcs.114.18.3387

Liu, 1995, Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells, Int. J. Cancer, 60, 501, 10.1002/ijc.2910600413

Wong, 2016, In vivo imaging of protease activity by Probody therapeutic activation, Biochimie, 122, 62, 10.1016/j.biochi.2015.11.003

Roybal, 2016, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011

Zah, 2016, T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells, Cancer Immunol. Res., 4, 498, 10.1158/2326-6066.CIR-15-0231

Kloss, 2013, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells, Nat. Biotechnol., 31, 71, 10.1038/nbt.2459

Wilkie, 2012, Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32, 1059, 10.1007/s10875-012-9689-9

Lanitis, 2013, Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo, Cancer Immunol. Res., 1, 43, 10.1158/2326-6066.CIR-13-0008

Fedorov, 2013, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses, Sci. Transl. Med., 5, 215ra172, 10.1126/scitranslmed.3006597

Liu, 2015, Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice, Cancer Res., 75, 3596, 10.1158/0008-5472.CAN-15-0159

Caruso, 2015, Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity, Cancer Res., 75, 3505, 10.1158/0008-5472.CAN-15-0139

Chmielewski, 2004, T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity, J. Immunol., 173, 7647, 10.4049/jimmunol.173.12.7647

Johnson, 2015, Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma, Sci. Transl. Med., 7, 275ra22, 10.1126/scitranslmed.aaa4963

Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol. Ther., 21, 904, 10.1038/mt.2013.17

Engels, 2003, Retroviral vectors for high-level transgene expression in T lymphocytes, Hum. Gene Ther., 14, 1155, 10.1089/104303403322167993

Ghani, 2009, Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media, Hum. Gene Ther., 20, 966, 10.1089/hum.2009.001

Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor, J. Immunother., 32, 689, 10.1097/CJI.0b013e3181ac6138

Cieri, 2013, IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors, Blood, 121, 573, 10.1182/blood-2012-05-431718

Alcantar-Orozco, 2013, Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer, Hum. Gene Ther. Methods, 24, 310, 10.1089/hgtb.2013.022